neobookRx
DrugsLevel 4 LocalisationS2NASEML

Azelastine

Histamine receptor antagonistAntihistamine

Indications

Registered South African indications:

  • Allergic rhinitis

Cautions

Contraindications

  • Hypersensitivity to the active ingredient or any of its excipients

Cautions

  • Pregnancy
  • Breastfeeding

Adult dosage

Forms avail. in SA and covered in this monograph: nas

Seasonal and perennial allergic rhinitis

  • Nasal (nas): 0.14mg (1 actuation) per nostril, 12hrly

Paediatric dosage

Paed. forms avail. in SA and covered in this monograph: nas

Seasonal and perennial allergic rhinitis

Younger than 6 years

  • Not established for use

Older than 6 years

  • See adult dosage

Special populations

Pregnancy

  • Caution
  • At high oral doses in animals, 500 times the proposed oral human daily dose, foetal death, growth retardation and an increased incidence of skeletal abnormalities occurred during reproduction toxicity testing. Due to the nasal route of administration and the low dose administered, minimal systemic exposure can be expected. However as with all medicines caution should be exercised with use during pregnancy

Breastfeeding

  • Caution 
  • Due to the nasal route of administration and the low dose administered, minimal systemic exposure can be expected. However as with all medicines caution should be exercised with use during breastfeeding

Fertility

  • There is only limited data with regard to fertility

Renal Impairment

Hepatic Impairment

Elderly

Porphyria Information

Drugs in Sport

  • Permitted - No warning

Adverse reactions

Respiratory Disorders

  • Irritation of nasal mucousa
  • Stinging
  • Itching
  • Sneezing
  • Epistaxis

Gastrointestinal Disorders

  • Bitter taste in mouth
  • Nausea

Skin and Subcutaneous Tissue Disorders

  • Rash
  • Pruritis
  • Urticaria

Interactions

No information available

Monitoring

None routine

Mechanism of action

Azelastine is a selective H1-receptor antagonist that inhibits release of histamine and other inflammatory mediators. It also increases motility of bronchial epithelial cilia, thus improving mucous clearance.

Dosage forms

  • Nasal spray

Formulation

Nasal spray (per ml) 0.14mg

  • Rhinolast (Mylan) originator

Also available in the following form: Eye drop

References

1. SmPC: Rhinolast Nasal Spray, Mylan Products Limited:Last updated on eMC: 29 May 2018; Downloaded online 13 Nov 2018 [https://drive.google.com/drive/u/0/folders/1euMPdGSf959_b9mnjQm6RmnIHaskIx8-] 2. Drugs.com: Azelastine; Downloaded online 13 Nov 2018 [https://drive.google.com/drive/u/0/folders/1euMPdGSf959_b9mnjQm6RmnIHaskIx8-] 3. PI: Rhinolast Nasal Spray, Meda Pharma SA (Pty) Ltd:Date of registration 17 Feb 1997 [https://drive.google.com/drive/u/0/folders/1euMPdGSf959_b9mnjQm6RmnIHaskIx8-] 4. https://www.uptodate.com/contents/azelastine-nasal-drug-information?source=search_result&search=azelastine&selectedTitle=1~21 (last accessed 18/12/2018) 5. NAPOS The Drug Database for Acute Porphyria: R01AC03 Azelastine; Accessed online 18 Dec 2018 [http://www.drugs-porphyria.org/languages/UnitedKingdom/s3.php?atc_code=R01AC03&l=gbr] 6. South African Institute for Drug-Free Sport; Rhinolast; Accessed online 18 Dec 2018 [http://www.drugfreesport.org.za/online-medication-check/] 7. SmPC: Dymista 137 micrograms/ 50 micrograms per actuation Nasal Spray, Mylan; Last updated on eMC: 10 Dec 2019; Downloaded online: 05 May 2020 [https://www.medicines.org.uk/emc/product/9450/smpc/print]

Brands & products

1 product · cached snapshot
Trade names (1)
  • Rhinolast

NASNasal spray· 1 product

from R95.20
ProductStrengthPackApplicantMin price
Rhinolast Nasal Spray0.14 mg/ml10Mylan (Pty) LtdR95.20

Medical aid coverage

data not yet integrated
Discovery Health
not yet integrated
  • Comprehensive Series—
  • Executive Plan—
  • KeyCare Series—
  • Priority Series—
  • Saver Series—

Formulary scraper pending — coverage tier, co-pay and authorisation requirements will appear here once data is ingested.

Bonitas Medical Fund
not yet integrated
  • BonClassic—
  • BonComprehensive—
  • BonEssential—
  • BonFit Select—
  • BonSave—
  • BonStart—

Formulary scraper pending — coverage tier, co-pay and authorisation requirements will appear here once data is ingested.

GEMS — Government Employees Medical Scheme
not yet integrated
  • Beryl—
  • Emerald—
  • Onyx—
  • Ruby—
  • Sapphire—
  • Tanzanite One—

Formulary scraper pending — coverage tier, co-pay and authorisation requirements will appear here once data is ingested.

POLMED — Police Medical Aid Scheme
not yet integrated
  • Aquarium Option—
  • Efficiency Option—
  • Marine Option—

Formulary scraper pending — coverage tier, co-pay and authorisation requirements will appear here once data is ingested.

Interacts with 1 known drugs

Check against other drugs →

Cited in 1 document

NeoHealth® ID 15828 · updated 10/15/2022